MXCT MaxCyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MXCT

Price (delayed)

$1.23

Market cap

$131.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.37

Enterprise value

$134.69M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 33

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to ...

Highlights
The EPS has grown by 12% from the previous quarter and by 8% YoY
MXCT's net income is up by 12% QoQ and by 6% YoY
MXCT's quick ratio is up by 46% since the previous quarter but it is down by 3.6% year-on-year
The equity has contracted by 16% YoY and by 2.1% from the previous quarter
The company's gross profit fell by 15% YoY and by 3% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: https://maxcyte.com
Peers: ABT TMO DHR ISRG

Key stats

What are the main financial stats of MXCT

MXCT stock price

How has the MaxCyte stock price performed over time
Intraday
2.5%
1 week
5.13%
1 month
43.36%
1 year
-48.54%
YTD
-20.65%
QTD
75.09%

Financial performance

How have MaxCyte's revenue and profit performed over time
Revenue
$32.29M
Gross profit
$25.99M
Operating income
-$45.79M
Net income
-$39.12M
Gross margin
80.5%
Net margin
-121.2%
The company's gross profit fell by 15% YoY and by 3% QoQ
The revenue has declined by 14% year-on-year and by 2.2% since the previous quarter
The operating income has increased by 12% since the previous quarter and by 11% year-on-year
MXCT's net income is up by 12% QoQ and by 6% YoY

Price vs fundamentals

How does MXCT's price correlate with its fundamentals

Growth

What is MaxCyte's growth rate over time

Valuation

What is MaxCyte stock price valuation
P/E
N/A
P/B
0.78
P/S
4.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.17
The EPS has grown by 12% from the previous quarter and by 8% YoY
MXCT's P/B is 62% below its 5-year quarterly average of 2.0 and 16% below its last 4 quarters average of 0.9
The equity has contracted by 16% YoY and by 2.1% from the previous quarter
MXCT's price to sales (P/S) is 67% less than its 5-year quarterly average of 12.2 and 16% less than its last 4 quarters average of 4.7
The revenue has declined by 14% year-on-year and by 2.2% since the previous quarter

Efficiency

How efficient is MaxCyte business performance
The return on equity has declined by 11% year-on-year but it is up by 9% since the previous quarter
The ROIC has increased by 10% from the previous quarter but it has decreased by 2.6% YoY
The ROS has grown by 10% from the previous quarter but it has contracted by 9% YoY
The ROA has contracted by 9% YoY but it has grown by 9% from the previous quarter

Dividends

What is MXCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MXCT.

Financial health

How did MaxCyte financials performed over time
MXCT's quick ratio is up by 46% since the previous quarter but it is down by 3.6% year-on-year
The current ratio is up by 45% since the previous quarter
MXCT's debt is 90% less than its equity
The equity has contracted by 16% YoY and by 2.1% from the previous quarter
MaxCyte's debt to equity has increased by 11% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.